Blair William & Co. IL Decreases Stock Position in Certara, Inc. (NASDAQ:CERT)

Blair William & Co. IL cut its holdings in Certara, Inc. (NASDAQ:CERT) by 14.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,655 shares of the company’s stock after selling 2,961 shares during the period. Blair William & Co. IL’s holdings in Certara were worth $245,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in CERT. Blue Trust Inc. bought a new stake in shares of Certara in the 2nd quarter worth about $26,000. Pineridge Advisors LLC bought a new stake in shares of Certara in the 4th quarter worth about $28,000. Innealta Capital LLC bought a new stake in shares of Certara in the 2nd quarter worth about $36,000. YHB Investment Advisors Inc. bought a new stake in shares of Certara in the 1st quarter worth about $47,000. Finally, SG Americas Securities LLC bought a new stake in shares of Certara in the 2nd quarter worth about $226,000. 73.96% of the stock is currently owned by institutional investors.

Insider Transactions at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CERT shares. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Friday. Robert W. Baird cut their price target on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Barclays cut their price target on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. JMP Securities reiterated a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. Finally, KeyCorp cut their price target on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Six analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $17.79.

Certara Price Performance

Shares of CERT stock opened at $11.75 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. The company has a market capitalization of $1.89 billion, a P/E ratio of -30.13, a P/E/G ratio of 5.17 and a beta of 1.49. The company’s 50-day simple moving average is $12.73 and its two-hundred day simple moving average is $15.11. Certara, Inc. has a one year low of $10.35 and a one year high of $19.87.

Certara (NASDAQ:CERT) last issued its earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. Certara’s revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 earnings per share. As a group, equities analysts anticipate that Certara, Inc. will post 0.27 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.